Pfizer

July 30, 2019August 26, 2019

FDA Approves Rituxan Biosimilar Ruxience for Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for all non-Hodgkin’s lymphoma indications of its reference product, the company announced. The therapy ... Read more

May 31, 2018

Xalkori Named Breakthrough Therapy for Difficult-to-Treat Rare Lymphoma

News

The U.S. Food and Drug Administration granted breakthrough therapy designation to Pfizer’s Xalkori (crizotinib) for the treatment of a subgroup of difficult-to-treat systemic anaplastic large cell lymphoma (ALCL). The FDA’s ... Read more

January 29, 2018January 29, 2018

Pfizer’s Rituxan Biosimilar Equally Effective at Treating Follicular Lymphoma, Trial Shows

News

Pfizer‘s biosimilar therapy candidate PF-05280586 has shown equal effectiveness as Rituxan (rituximab) at treating indolent follicular lymphoma in a Phase 3 trial, the company announced. Indolent, or slow-growing, follicular lymphoma is ... Read more

January 19, 2018January 19, 2018

Phase 1/2 Trial to Test Yescarta-Utomilumab Combo in Refractory Large B-cell Lymphoma

News

A new multicenter Phase 1/2 trial will evaluate an immunotherapy combination of Yescarta (axicabtagene ciloleucel) and utomilumab for the treatment of patients with refractory large B-cell lymphoma. The trial, part of a clinical ... Read more

September 5, 2017

FDA Approves Mylotarg for Adults and Children with AML

News

The U.S. Food and Drug Administration has approved Pfizer’s Mylotarg (gemtuzumab ozogamicin) for adults and children with acute myeloid leukemia (AML) whose cancer carries the CD33 marker. In adults, Mylotarg ... Read more

August 19, 2017August 19, 2017

FDA Approves Besponsa for Acute Lymphoblastic Leukemia

News

Pfizer Inc. announced that the FDA has approved Besponsa (inotuzumab ozogamicin) for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). “For adult patients with B-cell ALL whose ... Read more

July 13, 2017

FDA Committee Recommends Approval of Mylotarg to Treat Newly Diagnosed AML

News

The Oncologic Drug Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) supports the approval of Pfizer’s Mylotarg (gemtuzumab ozogamicin), in combination with standard chemotherapy, for the treatment ... Read more

July 6, 2017

EU Approves Besponsa for Adults with B-Cell Acute Lymphoblastic Leukemia

ALL, News

The European Union has approved Pfizer‘s Besponsa as a treatment for adults with a type of B-cell leukemia. The authorization applies to patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic ... Read more

December 7, 2015May 13, 2016

Leukemia and Lymphoma Society in 3 New Efforts to Treat, Cure Blood Cancers

News

The Leukemia & Lymphoma Society (LLS) recently announced three efforts, including two partnerships, to advance groundbreaking research and patient support, reinforcing its leadership in continuing efforts to find cures and new therapies for ... Read more